


Stabilis



Hydrochlorothiazide



Vakaus lääkevalmisteen

		40 mg ® = ?	SyrSpend SF PH4® Dry Injektioneste >> 20 mL	1,3g 18-26°C		60		4256
		40 mg ® = ?	SyrSpend SF PH4® Dry Injektioneste >> 20 mL	1,3g 2-8°C		60		4256
		50 mg ® = ?	Sitruunahappo 870 mg Natriumfosfaatti 835 mg Sokerivesi 32 g Metyyliparabeeni 77 mg Propyleeniglykoli 275 mg Appelsiiniaromi 52 mg Puhdistettu vesi 73.6 g	25°C		180		3399
		200 mg	Glyseroli 20 g Metyyliselluloosa 1000 1 g Sitruunahappo 4% pH=3>3,5 Puhdistettu vesi >> 100 ml	5°C		21		3361
		750 mg ® = ?	SyrSpend SF PH4® >> 150 ml	2-8°C		90		3910
		300 mg ® = ?	SyrSpend SF PH4® >> 150 ml	2-8°C		90		4177
		750 mg ® = ?	SyrSpend SF PH4® >> 150 ml	20-25°C		90		3910
		50 mg ® = ?	Sitruunahappo 870 mg Natriumfosfaatti 835 mg Sokerivesi 32 g Metyyliparabeeni 77 mg Propyleeniglykoli 275 mg Appelsiiniaromi 52 mg Puhdistettu vesi 73.6 g	25°C		180		3399



Stabilis seoksissa

	SyrSpend SF® >> 20 ml	25°C	?	Spironolactone : Jauhe ® = ? 100 mg	90	4198
	SyrSpend SF® >> 20 ml	4°C	?	Spironolactone : Jauhe ® = ? 100 mg	90	4198
	OraPlus® / OraSweet® (1:1) 120 ml	25°C		Spironolactone : Tabletit ®=? (Mylan Pharmaceutical) 600 mg	60	2435
	OraPlus® / OraSweet SF® (1:1) 120 ml	25°C		Spironolactone : Tabletit ®=? (Mylan Pharmaceutical) 600 mg	60	2435
	Kirsikkasiirappi/sokerivesi (1:4) 120 ml	25°C		Spironolactone : Tabletit ®=? (Mylan Pharmaceutical) 600 mg	60	2435
	OraPlus® / OraSweet® (1:1) 120 ml	5°C		Spironolactone : Tabletit ®=? (Mylan Pharmaceutical) 600 mg	60	2435
	OraPlus® / OraSweet SF® (1:1) 120 ml	5°C		Spironolactone : Tabletit ®=? (Mylan Pharmaceutical) 600 mg	60	2435
	Kirsikkasiirappi/sokerivesi (1:4) 120 ml	5°C		Spironolactone : Tabletit ®=? (Mylan Pharmaceutical) 600 mg	60	2435



Viitteet

	tyyppi	julkaisu
2435	Lehti	Allen LV, Jr, Erickson MA, Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
3361	Lehti	Santovenia A, Hernandez-Paiz Z, Farina J.B. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int J Pharm 2012 ; 423: 360-364.
3399	ilmoitus	Li Y.Y, Postma D.J, Wagenaar H.W.G. Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children. EAHP Congress Paris 2013
3910	Lehti	Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. EJHP 2016 ; 23: 352-358.
4177	Lehti	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4198	Lehti	Uriel M, Gomez-Rincon C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. Pharmazie 2018 73;196-201
4256	Lehti	Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A. Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients. Pharmaceutics 2019 ;11,190:



Sanakirja

	Diureetit		Oraaliliuos
	Vakaus lääkevalmisteeseen		Astia
	Origine		Apuaine
	Lämpötila		Säilytys
	Vakauden kesto		biologisesti
	ristiriitaisia tietoja		Viitteet
	Lasi		Jauhe
	Suojattava valolta		Päivä
	Muovipullo		Ei määritetty
	Stabilus seoksissa		Yhdiste
	Viitteet		Sanakirja